HakkaDedi
voted
Good day, traders. Happy Wednesday, Aug 7th. The market is rebounding thanks to a lighter earnings week, and lower volatility overall. My name is Kevin Travers; here are stories herd on Wall Street: these are today's moovin' stonks.
$Novo-Nordisk A/S (NVO.US)$, the Wegovy and Ozempic seller saw its stock fell 7% after the firm said on Wednesday its profit rose 3% to 20 billion Danish kroner ($2.93 billion), or 4.49 kroner a share...
$Novo-Nordisk A/S (NVO.US)$, the Wegovy and Ozempic seller saw its stock fell 7% after the firm said on Wednesday its profit rose 3% to 20 billion Danish kroner ($2.93 billion), or 4.49 kroner a share...
14
6
HakkaDedi
voted
Timetable of IPO
Figure 1: IPO timetable of EEHB
Source: $ELRIDGE (0318.BMS)$ IPO prospectus
-Will be listed on the ACE Board
Full IPO Video on YouTube (Chinese version): - YouTube
Info of IPO
Enlarged no. of shares upon listing: 2000M
IPO price: RM0.29
Market capitalization: RM580M
Estimated funds to raise from Public Issue: RM101.5M
PE ratio = 24.6x (based on FY2023)
Business Model
Figure 2: Business model of EEHB
S...
Figure 1: IPO timetable of EEHB
Source: $ELRIDGE (0318.BMS)$ IPO prospectus
-Will be listed on the ACE Board
Full IPO Video on YouTube (Chinese version): - YouTube
Info of IPO
Enlarged no. of shares upon listing: 2000M
IPO price: RM0.29
Market capitalization: RM580M
Estimated funds to raise from Public Issue: RM101.5M
PE ratio = 24.6x (based on FY2023)
Business Model
Figure 2: Business model of EEHB
S...
+6
18
1
HakkaDedi
liked
$NVIDIA (NVDA.US)$ anticipates the quarterly report. Bear and Bull battle on.
1
$Adaptimmune Therapeutics (ADAP.US)$ looks promising 👀
HakkaDedi
liked
$Adaptimmune Therapeutics (ADAP.US)$ FDA: Granted Approval of Tecelra to Adaptimmune, LLC
Reuters· 3 mins ago
FDA: Approves First Gene Therapy to Treat Adults With Metastatic Synovial Sarcoma
Reuters· 1 min ago
FDA: Granted Tecelra Orphan Drug, Regenerative Medicine Advanced Therapy & Priority Review Designations
Reuters· 3 mins ago
FDA: Approves First Gene Therapy to Treat Adults With Metastatic Synovial Sarcoma
Reuters· 1 min ago
FDA: Granted Tecelra Orphan Drug, Regenerative Medicine Advanced Therapy & Priority Review Designations
4
HakkaDedi
reacted to
$Longeveron (LGVN.US)$ Break 5.25? Looking for 5.83, 6.40 NFA
8
5
HakkaDedi
liked
Traders should always know when they plan to enter or exit a trade before they execute. By using stop losses effectively, a trader can minimize not only losses but also the number of times a trade is exited needlessly. In conclusion, make your battle plan ahead of time and keep a journal of your wins and losses.
https://www.investopedia.com/articles/trading/09/risk-management.asp
https://www.investopedia.com/articles/trading/09/risk-management.asp
1
HakkaDedi
voted
Hi, mooers!
Kucingko Bhd is expected to officially start trading on July 26. According to the animation production house company, it has received 21,929 applications for 2.5 billion shares, far exceeding the 25 million shares available for public subscription.
How will the market react to the IPO results? Make your guess now!
🎁 Rewards:
● An equal share of 3,000 points: Predict the percentage change in Kucingko's closing pr...
Kucingko Bhd is expected to officially start trading on July 26. According to the animation production house company, it has received 21,929 applications for 2.5 billion shares, far exceeding the 25 million shares available for public subscription.
How will the market react to the IPO results? Make your guess now!
🎁 Rewards:
● An equal share of 3,000 points: Predict the percentage change in Kucingko's closing pr...
102
110
HakkaDedi
voted
Morning traders, Happy Monday, where the market is open and working properly following a blue screen filled Friday. Investors are pricing in the aftermath of the closest to election day step down of a presumptive nominee: Biden is out.
$Verizon (VZ.US)$ stock traded 6% lower on Monday after it reported fiscal second-quarter results. Its sales increased 0.6% yearly to $32.8 billion, marginally missing the analys...
$Verizon (VZ.US)$ stock traded 6% lower on Monday after it reported fiscal second-quarter results. Its sales increased 0.6% yearly to $32.8 billion, marginally missing the analys...
36